Trial Profile
Safety and efficacy of eribulin mesylate in patients with extra cranial metastatic breast cancer
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2016
Price :
$35
*
At a glance
- Drugs Eribulin (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Jul 2016 New trial record
- 07 Jun 2016 Preliminary results (n=30) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology